Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.

Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Déjou C, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou JF, Bastid J, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N.

Cell Rep. 2019 May 21;27(8):2411-2425.e9. doi: 10.1016/j.celrep.2019.04.091.


The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.

Laprevotte E, Cochaud S, du Manoir S, Lapierre M, Dejou C, Philippe M, Giustiniani J, Frewer KA, Sanders AJ, Jiang WG, Michaud HA, Colombo PE, Bensussan A, Alberici G, Bastid J, Eliaou JF, Bonnefoy N.

Oncotarget. 2017 Dec 6;8(69):113360-113372. doi: 10.18632/oncotarget.23008. eCollection 2017 Dec 26.


IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.

Merrouche Y, Fabre J, Cure H, Garbar C, Fuselier C, Bastid J, Antonicelli F, Al-Daccak R, Bensussan A, Giustiniani J.

Oncotarget. 2016 Aug 16;7(33):53350-53361. doi: 10.18632/oncotarget.10804.


Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism.

Sundström P, Stenstad H, Langenes V, Ahlmanner F, Theander L, Ndah TG, Fredin K, Börjesson L, Gustavsson B, Bastid J, Quiding-Järbrink M.

Cancer Immunol Res. 2016 Mar;4(3):183-93. doi: 10.1158/2326-6066.CIR-15-0050. Epub 2016 Jan 19.


CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression.

Bonnefoy N, Bastid J, Alberici G, Bensussan A, Eliaou JF.

Oncoimmunology. 2015 Feb 3;4(5):e1003015. eCollection 2015 May.


IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells.

Mombelli S, Cochaud S, Merrouche Y, Garbar C, Antonicelli F, Laprevotte E, Alberici G, Bonnefoy N, Eliaou JF, Bastid J, Bensussan A, Giustiniani J.

Sci Rep. 2015 Jul 8;5:11874. doi: 10.1038/srep11874.


Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.

Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, Laheurte C, Cochaud S, Laprevotte E, Funck-Brentano E, Hemon P, Gros L, Bec N, Larroque C, Alberici G, Bensussan A, Eliaou JF.

Cancer Immunol Res. 2015 Mar;3(3):254-65. doi: 10.1158/2326-6066.CIR-14-0018. Epub 2014 Nov 17.


Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis.

Bastid J, Bonnefoy N, Eliaou JF, Bensussan A.

Oncoimmunology. 2014 Mar 27;3:e28273. eCollection 2014.


IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2.

Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye AM, Curé H, Mascaux C, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A, Bastid J.

Sci Rep. 2013 Dec 9;3:3456. doi: 10.1038/srep03456.


CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8(+) CD39(+) regulatory T cells.

Boer MC, van Meijgaarden KE, Bastid J, Ottenhoff TH, Joosten SA.

Eur J Immunol. 2013 Jul;43(7):1925-32. doi: 10.1002/eji.201243286. Epub 2013 May 29.


ENTPD1/CD39 is a promising therapeutic target in oncology.

Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A.

Oncogene. 2013 Apr 4;32(14):1743-51. doi: 10.1038/onc.2012.269. Epub 2012 Jul 2. Review.


EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations.

Bastid J.

Cancer Metastasis Rev. 2012 Jun;31(1-2):277-83. doi: 10.1007/s10555-011-9344-6. Review.


TWISTing an embryonic transcription factor into an oncoprotein.

Ansieau S, Morel AP, Hinkal G, Bastid J, Puisieux A.

Oncogene. 2010 Jun 3;29(22):3173-84. doi: 10.1038/onc.2010.92. Epub 2010 Apr 12. Review.


The SNAIL family member SCRATCH1 is not expressed in human tumors.

Bastid J, Bouchet BP, Ciancia C, Pourchet J, Audoynaud C, Grelier G, Puisieux A, Ansieau S.

Oncol Rep. 2010 Feb;23(2):523-9.


[Role of the epithelial-mesenchymal transition during tumor progression].

Ansieau S, Caron de Fromentel C, Bastid J, Morel AP, Puisieux A.

Bull Cancer. 2010 Jan;97(1):7-15. doi: 10.1684/bdc.2009.1025. French.


Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus.

Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, Fabien N, Cochat P, Pouteil-Noble C, Trolliet P, Durieu I, Tebib J, Kassai B, Ansieau S, Puisieux A, Eliaou JF, Bonnefoy-Bérard N.

Nat Immunol. 2009 Jul;10(7):778-85. doi: 10.1038/ni.1741. Epub 2009 May 31. Retraction in: Nat Immunol. 2014 Sep;15(9):894.


Early origin of cancer metastases: dissemination and evolution of premalignant cells.

Ansieau S, Hinkal G, Thomas C, Bastid J, Puisieux A.

Cell Cycle. 2008 Dec;7(23):3659-63. Epub 2008 Dec 19. Review.


Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence.

Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, Valsesia-Wittmann S, Caron de Fromentel C, Puisieux A.

Cancer Cell. 2008 Jul 8;14(1):79-89. doi: 10.1016/j.ccr.2008.06.005.


Should we consider cancers as embryonic diseases or as consequences of stem-cell deregulation?

Bastid J, Puisieux A, Ansieau S.

Clin Med Oncol. 2008;2:363-6. Epub 2008 Apr 29.

Supplemental Content

Loading ...
Support Center